H.C. Wainwright analyst Andrew Fein said there was "confusion and split sentiment" about Catalyst Pharmaceuticals' Firdapse heading into the PDUFA date given the uncertainty about the actions of privately-held Jacobus Pharmaceutical. However, he believes the FDA approval has "officially settled the race" between Catalyst and Jacobus and should provide Firdapse with a first-to-market, seven-year exclusivity period to prevent any compounding of the same drug by Jacobus. Following the approval news, Fein reiterates his Buy rating and $6 price target on Catalyst shares.